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Abstract: We investigated cerebrospinal fluid (CSF) expression of inflammatory cytokines and
their relationship with spontaneous intracerebral and intraventricular hemorrhage (ICH, IVH) and
perihematomal edema (PHE) volumes in patients with acute IVH. Twenty-eight adults with IVH
requiring external ventricular drainage for obstructive hydrocephalus had cerebrospinal fluid (CSF)
collected for up to 10 days and had levels of interleukin-1α (IL-1α), IL-1β, IL-6, IL-8, IL-10, tumor
necrosis factor-α (TNFα), and C-C motif chemokine ligand CCL2 measured using enzyme-linked
immunosorbent assay. Median [IQR] ICH and IVH volumes at baseline (T0) were 19.8 [5.8–48.8]
and 14.3 [5.3–38] mL respectively. Mean levels of IL-1β, IL-6, IL-10, TNF-α, and CCL2 peaked early
compared to day 9–10 (p < 0.05) and decreased across subsequent time periods. Levels of IL-1β,
IL-6, IL-8, IL-10, and CCL2 had positive correlations with IVH volume at days 3–8 whereas positive
correlations with ICH volume occurred earlier at day 1–2. Significant correlations were found with
PHE volume for IL-6, IL-10 and CCL2 at day 1–2 and with relative PHE at days 7–8 or 9–10 for IL-1β,
IL-6, IL-8, and IL-10. Time trends of CSF cytokines support experimental data suggesting association
of cerebral inflammatory responses with ICH/IVH severity. Pro-inflammatory markers are potential
targets for injury reduction.
Keywords: intracerebral hemorrhage; intraventricular hemorrhage; neuroinflammation; cytokines;
cerebrospinal fluid
1. Introduction
Intraventricular hemorrhage and ensuing hydrocephalus complicate spontaneous
intracerebral hemorrhage in up to 45% of ICH patients, and independently contribute
to poor outcomes [1–3]. Acute hydrocephalus, mass effect and intracranial hypertension
cause the primary damage, whereas the inflammatory response likely contributes to the
progression of secondary injury [4].
An aseptic inflammatory response in CSF has been demonstrated in experimental
and clinical ICH/IVH [4–6], and transient increases in inflammatory cytokines in CSF
have been described in small cohorts with aneurysmal SAH [7–10]. Elevations in serum
inflammatory markers following spontaneous ICH have been reported in clinical stud-
ies and were found to correlate with both radiographic parameters of brain injury and
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clinical outcomes [11–14]. The investigation of inflammatory cytokines from within the
central nervous system in ICH is limited predominantly to experimental models, with little
information regarding the expression of cytokines within the ventricular cavity [15–17]. Cy-
tokines and chemokines have been implicated in inflammatory models of ICH as mediators
of increased vascular permeability, inducing edema formation [13,17,18], recruitment of
leukocytes to the brain, and in the case of TNF-α to direct cytotoxic effects and activation of
other bioactive compounds [19,20]. The cytokine response is a potential therapeutic target
in ICH and modifiable with commercially available antibodies. Therefore, understanding
the molecular mechanisms underlying secondary injury after clinical ICH could guide the
development and application of novel therapies.
In this study, we evaluated the early expression of cytokine levels in CSF among
patients with spontaneous IVH with or without parenchymal ICH. We hypothesized
that the extravasation of red blood cells into the intraventricular compartment and their
subsequent lysis leads to activation of the immune response, resulting in elevated CSF
cytokines, and that this response is proportional to IVH volume, and clinical severity
2. Materials and Methods
2.1. Study Design
This was a prospective three-center study of 28 adults with severe spontaneous IVH
requiring an EVD for obstructive hydrocephalus. We excluded patients with ruptured
aneurysm, tumors, and other brain lesions which could have contributed to ICH, as well
as any patient with bacterial ventriculitis/meningitis (defined by fever and a positive
cerebrospinal fluid culture) during the CSF collection period. EVDs were placed as a part
of routine clinical care in patients with symptomatic hydrocephalus.
2.2. Measurements
CSF and blood samples were collected for analysis daily starting on day 1 and for up
to 10 days after ICH/IVH symptom onset, depending on patient clinical status and site.
CSF samples were centrifuged immediately at 2000× g for 10 min, and the supernatant
was stored at −80 ◦C. Using the validated Luminex assay (R&D System, Minneapolis, MN,
USA), we measured concentrations of IL-1α, IL-1β, IL-6, IL-8, IL-10, TNF-α, and CCL2
(aka MCP-1) in CSF. Serum WBC was also recorded for the first 2 days. All biomarker
measurements were performed blinded to clinical and neuroimaging findings.
Non-contrast CT scans performed within 24 h of presentation (T0) and at end of CSF
collection +/− 24 h (Te) were used to measure IVH, ICH, and PHE volumes by a trained
image reader blinded to clinical outcomes using semi-automated, computerized volumetric
analysis on an open source DICOM viewer software program for Mac (Osirix v. 4.1, Pixmeo;
Geneva, Switzerland). The software adjusts for changes in slice thickness and thereby
corrects for different CT techniques across centers. The distinction between hemorrhage
and surrounding edema was made according to specific signal density on CT slices, with
hyperdensity representing hematoma and hypodensity in a PHE distribution considered
to represent brain edema (Hounsfield unit (HU) range of 5 to 33) [21]. Areas of edema
were carefully distinguished from periventricular white matter disease. This technique
has been previously validated with high inter- and intra-observer reliability [21]. Absolute
PHE volume was determined by subtracting the hemorrhage volume from the total lesion
volume. Relative PHE volume was calculated by dividing absolute PHE by hematoma
volume to control for ICH size, where ICH volume > 0.
Patient demographics and comorbidities were recorded at time of enrollment. Max-
imum temperature was recorded on each day of CSF collection. Any clinically proven
infection during the first week of admission was collected. Informed consent was pro-
vided by the most appropriate surrogate decision maker. This study was approved by the
Institutional Review Board of each center.
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2.3. Statistics
The primary outcome measure of the study was serial levels of inflammatory media-
tors in the ventricular fluid. We substituted half of the LLOD for cytokine values below
the detection limits of each assay (IL-1α: 1.38; IL-1β: 0.79; IL-10: 0.82; TNFα: 1.87; IL-6:
<9.0; IL-8: <6.4; CCL2: <5.6 pg/mL). Due to small sample size and lack of daily CSF levels
in all subjects, we report levels per 2-day interval where either a single level or the mean
of the level for both days was used for analysis (if one level was at LLOD, the higher
level was used). Associations between peak mean concentrations of cytokines for days
1–2 through days 9–10 and: ICH, IVH and PHE and relative PHE volume at admission
(T0) and at end of collection (Te) if a corresponding CT existed, and with age, and GCS on
admission were evaluated. Based on the distributions and availability of daily cytokine
values, Spearman correlations were used to describe the associations of the cytokine values
and these continuous measures at each day interval. Mann-Whitney tests were used to
compare initial/peak cytokine levels with indicators of occurrence of fever (any maximum
daily temperature > 38.3 degrees Celsius, elevated peripheral WBC count (>12 × 103), and
documented non-CNS infection within first week of admission. Comparisons of cytokine
levels between day interval 9–10 with other day intervals were made with a general linear
model analysis, taking into account within-patient correlations across day intervals.
As this was an exploratory analysis, no adjustment was made for multiple compar-
isons. Statistical analyses were performed using STATA (version 16.1, STATA Corp. College
Station, TX, USA). All analyses were two-tailed, and statistical significance was determined
by p < 0.05.
3. Results
3.1. Availability of Cytokine Measurements
The number of available measurements per patient varied with 5, 5, 8, 8, and 2 patients
having 1, 2, 3, 4 and 5 measurements, respectively. Thus, the number of measurements for
day intervals 1–2, 3–4, 5–6, 7–8, and 9–10 was 19, 21, 17, 16, and 8, respectively.
3.2. Cerebrospinal Fluid Levels of Inflammatory Cytokines
Median [IQR] time from symptom onset to first CSF sample was 1 [1–3] days (N = 28).
End of sample CT (Te) occurred at 8 [6–10] days (N = 22). Patient characteristics are shown
in Table 1. Mean CSF levels of IL-1β, IL-10, TNF-α, IL-6 and CCL2 all showed significant
differences in adjusted levels between day 1–2 compared to day 9–10, and for IL-1β and
IL-10 between all time points up to day 6 compared to days 9–10 (Figure 1, Table S1).
Significant decreases occur after day 1–2 for IL-10, TNF-α, and CCL2, and after day 3–4 for
IL-1β and IL-6. For IL1-alpha, and IL-8 levels, although there are patterns of increasing
and decreasing cytokine levels across days from admission, the differences in mean levels
were not statistically significant.
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Table 1. Baseline Characteristics and Outcomes.
Characteristic N = 28
Demographics:
Age, Mean (Standard Deviation) 59.4 (12.7)








Diabetes Mellitus 8 (29.6%)
Coronary Artery Disease 0
Prior stroke or ICH 4 (14.3%)
Hyperlipidemia 9 (32.1%)
Alcohol Abuse 6 (21.4%)
Cocaine use 3 (10.7%)
Anticoagulation 4 (14.3%)
Clinical History:
GCS on admission, median [IQR] 9 [6, 11]
ICH volume, median [IQR] (mL) 19.8 [5.8, 48.8]
IVH volume, median [IQR] (mL) 14.3 [5.3, 38]
ICH location: (lobar/basal ganglia/cerebellar/primary IVH) 5/18/3/2
Complications:
Fever (1st 7 days) 17 (60.7%)
WBC elevation (1st 7 days) 17 (60.7%)
Non-CNS infection 11 (39.3%)
Dead at discharge 10 (35.7%)
Abbreviations: ICH: intracerebral hemorrhage; GCS: Glasgow Coma Scale; IVH: intraventricular
hemorrhage; IQR: interquartile range; WBC: white blood cell count; CNS: central nervous system.
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Figure 1. Mean and 95% confidence interval levels of central inflammatory cytokines and chemo-
kines by day time periods: (a) IL-1α, (b) IL-1β, (c) IL-10, (d) TNF-α; (e) IL-6, (f) IL-8, (g) MCP-1 
(CCL2); (Number of samples): day 1–2 (19); day 3–4 (21); day 5–6 (17); day 7–8 (16); day 9–10 (8). *: 
p < 0.05 compared to day 9–10. 
Figure 1. Me and 95% confid nce interval levels of central inflammatory cytokines and chemokines
by day time periods: (a) IL-1α, (b) IL-1β, (c) IL-10, (d) TNF-α; (e) IL-6, (f) IL-8, (g) MCP-1 (CCL2);
(Number of samples): day 1–2 (19); day 3–4 (21); day 5–6 (17); day 7–8 (16); day 9–10 (8). *: p < 0.05
compared to day 9–10.
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3.3. Cytokine Expression and Correlations with Injury Severity
Table 2 shows Spearman correlation results between the radiographic volumes and
cytokine levels. Significant correlations occurred between IVH volume on admission (T0)
and levels of IL-6, IL-8, IL-10, and CCL2 and were largest on days 5–6 and 7–8 (Spearman’s
rho all >0.50; p < 0.05). ICH volume (T0) was significantly correlated with IL-1β, IL-6, IL-10,
and CCL2 at day 1–2 post onset. Statistically significant correlations were larger for total
blood volume (ICH plus IVH) than for each separately, for all cytokines predominantly
at day 1–2, except for IL-1α (day 3–4). PHE and/or relative PHE volume at T0 were
significantly correlated with elevations of most cytokines on day 1–2 for PHE (except IL-1
and TNF-α), and on day 7–8 or day 9–10 for relative PHE (except TNF-α and CCL2).
Table 2. Associations of Radiographic Volumes with Cerebrospinal Fluid Cytokine Levels in Intraventricular Hemorrhage
Patients by Days Post Hemorrhage Onset.
Days Post Hemorrhage Onset
1–2 (N = 19, 16) a 3–4 (N = 21, 17) 5–6 (N = 17, 14) 7–8 (N = 16, 13) 9–10 (N = 8, 6)
Cytokine Radiographic Variables b Corr c P d Corr p Corr p Corr p Corr p
IL-1alpha ICH Volume (mL) 0.34 0.15 0.34 0.13 0.20 0.44 0.15 0.58 −0.25 0.55
(pg/mL) IVH Volume (mL) −0.25 0.30 0.23 0.32 −0.18 0.50 0.22 0.41 0.08 0.85
PHE Volume (mL) 0.44 0.06 0.38 0.09 0.27 0.30 0.30 0.25 −0.25 0.55
Relative PHE Volume (%) 0.11 0.69 0.08 0.76 −0.23 0.43 0.62 0.02 0.13 0.80
Total Volume e (mL) 0.07 0.77 0.50 0.02 −0.04 0.88 0.10 0.71 −0.41 0.31
IL-1beta ICH Volume (mL) 0.51 0.03 0.09 0.68 0.24 0.35 0.18 0.50 −0.18 0.67
(pg/mL) IVH Volume (mL) 0.10 0.68 0.44 0.049 0.09 0.74 0.22 0.42 −0.07 0.87
PHE Volume (mL) 0.43 0.07 0.03 0.90 0.24 0.34 0.32 0.22 0.04 0.93
Relative PHE Volume (%) −0.35 0.19 −0.20 0.43 −0.16 0.58 0.60 0.03 0.60 0.21
Total Volume (mL) 0.60 0.006 0.34 0.14 0.25 0.34 0.17 0.52 −0.48 0.23
IL-10 ICH Volume (mL) 0.51 0.03 −0.18 0.43 −0.20 0.45 0.07 0.79 −0.25 0.56
(pg/mL) IVH Volume (mL) 0.06 0.80 0.48 0.03 0.63 0.007 0.39 0.14 −0.17 0.69
PHE Volume (mL) 0.48 0.04 −0.29 0.19 −0.11 0.67 0.21 0.43 −0.02 0.97
Relative PHE Volume (%) −0.18 0.52 −0.34 0.19 0.33 0.25 0.44 0.13 0.94 0.005
Total Volume (mL) 0.64 0.003 0.41 0.06 0.34 0.18 0.20 0.47 −0.61 0.11
TNF-alpha ICH Volume (mL) 0.42 0.08 −0.01 0.95 −0.06 0.83 −0.48 0.06 −0.50 0.21
(pg/mL) IVH Volume (mL) 0.22 0.37 0.26 0.26 0.08 0.77 0.25 0.35 0.25 0.55
PHE Volume (mL) 0.28 0.25 −0.08 0.73 −0.14 0.58 −0.44 0.09 −0.50 0.21
Relative PHE Volume (%) −0.50 0.05 −0.10 0.70 −0.40 0.16 0.13 0.67 NA NA
Total Volume (mL) 0.71 0.001 0.27 0.23 0.03 0.92 −0.24 0.38 −0.25 0.55
IL6 ICH Volume (mL) 0.57 0.01 0.01 0.95 −0.09 0.74 0.24 0.37 0.14 0.73
(pg/mL × 103) IVH Volume (mL) 0.00 1.00 0.49 0.03 0.54 0.03 0.27 0.31 −0.52 0.18
PHE Volume (mL) 0.48 0.04 −0.03 0.88 0.04 0.88 0.38 0.14 0.36 0.38
Relative PHE Volume (%) −0.24 0.36 −0.13 0.63 0.35 0.21 0.64 0.02 0.94 0.005
Total Volume (mL) 0.55 0.01 0.32 0.16 0.30 0.25 0.29 0.28 −0.40 0.32
IL8 ICH Volume (mL) 0.39 0.10 0.04 0.87 −0.16 0.53 −0.16 0.55 −0.25 0.55
(pg/mL × 103) IVH Volume (mL) 0.14 0.57 0.49 0.03 0.56 0.02 0.65 0.007 −0.02 0.96
PHE Volume (mL) 0.35 0.14 −0.02 0.94 −0.09 0.73 0.00 1.00 −0.04 0.93
Relative PHE Volume (%) −0.12 0.65 −0.12 0.66 0.20 0.48 0.60 0.03 0.71 0.11
Total Volume (mL) 0.52 0.02 0.29 0.20 0.22 0.39 0.14 0.59 −0.43 0.29
CCL2 ICH Volume (mL) 0.51 0.03 −0.07 0.76 −0.11 0.67 −0.05 0.85 −0.11 0.80
(pg/mL × 103) IVH Volume (mL) −0.13 0.61 0.43 0.05 0.27 0.29 0.73 0.001 0.07 0.87
PHE Volume (mL) 0.53 0.02 −0.17 0.46 −0.10 0.69 −0.01 0.97 −0.23 0.59
Relative PHE Volume (%) −0.12 0.66 −0.12 0.66 −0.01 0.97 0.22 0.47 −0.09 0.87
Total Volume (mL) 0.56 0.01 0.13 0.59 −0.14 0.59 0.32 0.22 0.36 0.39
a (N = x, y), where x is number of patients at this time point and y is number of patients for Relative PHE volume, where ICH Volume > 0.
b Measurements at T0 (Radiographic Volumes). c Spearman Correlation. d p-values are bold if p < 0.05. e Total Volume = ICH Volume + IVH
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3.4. Cytokine Expression and Clinical Characteristics
Comparisons of cytokine levels and clinical characteristics are shown in Supplemen-
tal Table S2. Day 1–2 levels of IL-10, TNF-α and CCL2 were inversely associated with
occurrence of WBC elevation during the first week after admission; day 3–4 levels of IL-1β,
IL-6, IL-8 and IL-10 were positively associated with febrile response during the first week.
WBC elevation in first week was inversely associated with CLL2 at day 7–8. IL-1α was
positively associated with in-hospital mortality (day 3–4) and IL-10 for day 5–6. Higher age
was positively associated with TNF-α and inversely with IL-1α, and admission GCS was
associated with TNF-α (day 1–2) and IL-8 (day 7–8) (Table S3). There were no significant
correlations between cytokine levels and ICH, IVH or PHE volumes at Te (data not shown).
4. Discussion
The presence of intraventricular blood induces inflammation, which may be an impor-
tant mechanism contributing to early and delayed brain injury in spontaneous ICH and is a
potential therapeutic target [5,21]. This hypothesis-generating study is one of relatively few
to investigate serial cytokine levels in CSF over the acute phase of spontaneous ICH with
IVH. We observed dynamic changes in CSF concentrations of several cytokines; baseline
ICH volume was associated with cytokine overexpression at day 1–2, baseline IVH volume
with cytokine overexpression at day 5–8, and baseline PHE and relative PHE with cytokine
overexpression at days 1–2 and 7–8 respectively. Cytokine levels were not associated with
these neuroimaging markers at end of CSF collection (Te, 6–10 days after presentation)
which may indicate that later expression does not follow secondary injury as well as in the
acute phase. Early cytokine elevation was positively associated with fever and inversely
associated with peripheral WBC counts within the first week. IL-1α and IL-10, which had
significant correlations with total blood volume and relative PHE, were also associated
with in-hospital mortality.
In aggressively managed IVH with EVD, the aseptic inflammatory response is reflected
by an early, IVH volume dependent elevation in CSF WBC at days 1–3 followed by a
gradual slower rate of WBC decline over the next six days [6]. This response mimics that
of the CSF cytokine elevations observed in this study. We reported temporal changes in
cytokines/chemokines with reference to day 9–10, although levels may still be altered
and do not likely reflect baseline CSF levels at this timepoint. Our observations are,
however, also consistent with a transient increase in similar CSF inflammatory cytokines
(TNF-α, interferon-γ, IL-1α, IL-1β, IL-2, IL-4, and IL-6) over 72 h reported in a small trial
of intraventricular tPA for IVH associated with aneurysmal SAH [10]. Levels of IL-1α,
TNF-α and IL-6 were relatively higher in CSF from control SAH patients compared to our
observed very low levels in spontaneous IVH, whereas IL-1β was higher in our cohort.
CSF IL-1β levels over first 7 days were even higher in a report of 41 adults with primary
ICH associated with IVH who did not receive tPA [22]. Whether such comparisons are
meaningful in a small sample, however, is not clear and may simply reflect sampling
variation. Levels of IL-6 were several magnitudes higher in both our and the SAH cohort
compared to other cytokines suggesting that the order of magnitude of elevation in CSF
cytokines is comparable between studies despite different etiologies of CSF inflammation.
Our study of acute changes in cytokines lacked a control group. However, stud-
ies in other disease states which included controls have investigated CSF inflammatory
markers and found that most cytokines were present in CSF at concentrations close to
or below the lower limit of detection of the assay [23]. In patients with possible normal
pressure hydrocephalus, median ventricular CSF concentrations were reported for IL-8
(19.1 [11.0] pg/mL), TNF-alpha (0), and CCL2 (758 [264.0] pg/mL). Other studies have
reported lumbar CSF concentrations from controls and report similar levels with CCL2
concentrations of 300–500 pg/mL [24,25]. The cytokine/chemokine concentrations re-
ported in our patients were one to two orders of magnitude larger than these control values
indicating significant elevations.
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4.1. Cytokine Levels and ICH and IVH Volume
In this study, admission ICH volume was larger than IVH volume and was correlated
with early CSF cytokine response (day 1–2), whereas admission IVH volume was corre-
lated with CSF cytokine overexpression at later time intervals (days 5–8). As hemorrhage
was present in both compartments from diagnostic CT, it is possible that the parenchy-
mal hematoma is an earlier source of CSF inflammation compared to ventricular blood.
Fibrinolysis causing gradual release of hematoma breakdown products may also induce
inflammation and may explain the delayed association between cytokine elevation and
IVH volume. Changes in the levels of cytokines in the CSF may be attributable to the
CNS resident cells or to infiltrating immunocytes from the peripheral blood, although the
source of cytokines in both the hematoma and CSF currently remain unknown. Possible
local sources include blood in the CSF or hematoma, the endothelial cells of the impaired
blood-brain or blood-CSF barrier, or activated microglia, astrocytes, and other CNS resident
cells. Release from immunocytes either in the parenchymal hematoma which spill over
into the CSF, or in the ventricular clot itself appear most consistent with the relationship
with ICH and IVH volumes.
Few studies have investigated CSF levels of cytokines following ICH. Kraus et al. [5]
found that soluble adhesion molecule (AM) concentrations ICAM-1 (sICAM-1) and VCAM-
1 (sVCAM-1) in CSF were maximal within the first hours after onset of basal ganglia ICH,
then decreased significantly on day 2 and only slightly increased thereafter. ICH volume
was significantly correlated with these levels in ventricular CSF but not in serum leading to
the conclusion that the ventricular inflammatory reaction appears to be pronounced early
after ICH onset and may be restricted to the central nervous system. Similar to our results,
early levels correlated more strongly with radiological/clinical data than did follow-up
measurements. From our Figure 1, we can conclude that most study variables diminished
over time, and were probably higher before EVD placement.
4.2. Comparison of Clinical CSF Cytokine Levels with Experimental Literature
From the experimental ICH literature, it is postulated that microglia, which are among
the first cells contributing to the innate immune response, become activated and develop
classic pro-inflammatory or alternative anti-inflammatory phenotypes, although this po-
larization may be an over-simplification [26]. Activated microglia do appear to be the
primary source of cytokines, chemokines, and other immunomodulatory molecules in
the brain [27] and TGF-β has been shown to reduce the pro-inflammatory responses in
microglia and improve outcomes in murine ICH models [28]. In both collagenase-induced
and autologous blood-induced models of ICH, the pro-inflammatory cytokines IL-1β, IL-6,
TNF [29,30] and inducible nitric oxide synthase (iNOS) [31] mRNA levels are generally
elevated in the acute phase, starting to rise as early as 3 h after ICH and peaking at 3
days [16]. Alternative activation markers, including IL-10, start to increase on day 1 after
ICH. As we lacked specific timing for our CSF samples relative to symptom onset and
samples were delayed until after EVD placement, we were not likely to observe very early
discriminatory differences in the production of pro-inflammatory cytokines such as TNF-α,
and IL-6, compared to anti-inflammatory cytokines like IL-10. The latter, secreted by both
macrophages and microglia as a feedback mechanism, suppresses pro-inflammatory cy-
tokine production, and similar to our CSF levels, is increased early in both blood and brain
tissue in patients with ICH [32].
4.3. Cytokine Levels and PHE Volume
Neutrophil infiltration and activation leads to the release of a variety of cytokines
and chemokines including IL-1α, IL-1β, TNF, IL-6, IL-8, and CCL2, some of which such as
IL-1β appear to be associated with development of PHE [17,33]. In our study, all cytokine
concentrations with exception of TNF had significant correlations with either PHE, and/or
relative PHE on diagnostic CT. Early day 1–2 significant correlations with PHE occurred
for cytokines which were also correlated with ICH volume on day 1–2, whereas significant
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correlations with relative PHE, which controls for the influence of ICH volume on PHE
volume, occurred later at day 7–8. Wang et al. reported that serum levels of IL-4, IL-6, and
IL-8 were positively correlated with severity of cerebral edema while IL-10 which peaked at
3 days after ICH was negatively correlated [13]. Discordance between CNS and peripheral
sampling of cytokines is not unusual, however, and levels of IL-10 may respond differently
locally and systemically.
4.4. Cytokine Levels and Indicators of Systemic Inflammation
This study found a positive correlation between CSF IL-1β, IL-6, IL-8 and IL-10 at
day 3–4 and fever, and an inverse correlation between IL-10, TNF-α, and CCL2 at day 1–2
and systemic pleocytosis in the first week. In clinical ICH, peripheral WBC count has been
associated with larger ICH volume, early neurological deterioration, and worse discharge
disposition [34] leading to the hypothesis that activation of the peripheral immune system
may enhance injury after ICH, and which is also consistent with experimental work [35].
Although we did not have data on individual contributions of leukocyte cell types, it is
noteworthy that higher CSF CCL2, the dominant chemokine for monocyte recruitment, was
correlated with lower WBC count in peripheral blood at day 1–2, and 7–8. This suggests
that CNS cytokine responses at least in CSF may lag behind peripheral immune activation,
and therefore is not a contradiction to the considerable evidence that inflammatory brain
lesions promote peripheral leukocytosis [36].
4.5. Cytokine Levels and Outcomes
Clinical studies have reported associations between serum inflammatory markers
in the acute phase of ICH, mainly CCL2, CXCL10, IL-6, IL-11, CRP, fibrinogen, and CSF
cytokines with hematoma expansion and early neurological decline [13,14]. Inflammation
is a potential therapeutic target, although in two adult cohorts of spontaneous intraventric-
ular hemorrhage, no correlation was found between CSF inflammatory measures (WBC,
corrected WBC, and cell index) and poor functional outcome (modified Rankin Score (mRS)
4–6) or mortality at 30 or 180 days after adjustment for other clinical severity factors. [4,6].
These results do not exclude more subtle effects of the inflammatory response.
Antibody-targeted modulation of clinical ICH includes cytokines studied in this
report, specifically reduction in ICH-induced brain edema with overexpression of IL-1
receptor antagonist [37] and augmenting anti-inflammatory cytokines, such as IL-10, in
brain tissues [37] to polarize microglia into a protective phenotype to minimize secondary
brain damage and promote brain repair [38]. The particular patterns of cytokine elevations
seen in this cohort do support potential therapeutic impact for both IL-1β and IL-10 based
on relatively high levels in the acute phase and significant correlations with all severity
indicators (ICH, IVH and PHE/relative PHE). Alternatively, elevated cytokines may only
be a marker of disease severity and may be reduced with fever control.
4.6. Limitations
This was a small descriptive study which is limited by lack of a control group or plasma
concentrations of cytokines. Therefore, we could not examine interactions of systemic
inflammation with that in the CNS. CSF expression levels are correlated with parameters
of injury and outcomes; however, this study cannot clarify whether these inflammatory
cytokines are derived from blood components leaked into the ventricles or originating from
an active immune reaction within the brain. The recovery of cytokines from ventricular
catheters also suffers from variability in catheter location relative to IVH, CSF drainage and
composition, and hospital protocol-based differences in sample collection times. Tractional
damage and effects of symptomatic hydrocephalus and its treatment (increase and then
decrease of ventricular size) could also be important variables in the observed changes.
The lack of adequate paired day-interval measurements, distributions of the cytokine levels
and small sample size precluded the use of parametric analyses for most of the analyses.
General linear model analyses were performed to account for within-patient correlations
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where appropriate, recognizing their limitations. Other sources of bias are lack of data
from all subjects at all time intervals.
Future research questions include associations of CSF inflammatory responses with
intracranial pressure, chronic hydrocephalus, permanent shunt requirement, and cognitive
outcome assessment. Despite a lack of statistical power, however, this study demonstrated
elevated levels of cytokines in CSF that were positively associated with ICH, PHE and IVH
volume and with a systemic febrile response.
5. Conclusions
In conclusion, although the clinical and laboratory correlations observed do not indi-
cate causal relationships, these data support the hypothesis that a significant inflammatory
host response in the CSF of patients with IVH contributes to the pathogenesis of this disease.
One therapeutic consequence of such findings is the proposition that early intraventricular
administration of anti-inflammatory or anti-cytokine strategies may mitigate inflammatory
complications after IVH.
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